Lipid nanoparticles (LNP)
The delivery form of choice for mRNA-based vaccines
In connection with the development of mRNA-based vaccines against Corona, lipid nanoparticles (LNPs) have shown to be a suitable delivery form. LNPs encapsulate and protect the delicate active ingredient and allow its transport to the target cells in the human body. Corona vaccines are the first large-scale use of mRNA and lipid nanoparticles in vaccination history.
KNAUER, mostly known for its liquid chromatography systems, also supplies production equipment for pharmaceutical lipid nanoparticles. This development was made possible by combining the company’s expertise in high pressure dosing and in laboratory systems engineering.
New and promising developments in medicine make pharmaceuticals and their active ingredients increasingly complex and bring new challenges. Oligonucleotides, for example, are very susceptible to degradation in the human body. LNPs have shown that they can form a stable basis for the administration of active ingredients like RNA, mRNA, siRNA, or DNA-based APIs. These types of APIs and optimization of delivery to the target cells are a very vivid field of research.
Read more >>>